← Back to Clinical Trials
Recruiting NCT07026240

NCT07026240 Post-operative Monitoring of Gastric Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07026240
Status Recruiting
Phase
Sponsor Suzhou Huhu Health & Technology Inc.
Condition Gastric Cancer
Study Type OBSERVATIONAL
Enrollment 258 participants
Start Date 2024-02-18
Primary Completion 2026-01-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
DNA test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 258 participants in total. It began in 2024-02-18 with a primary completion date of 2026-01-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is to determine the performance of non-invasive new multi-target biomarkers in the post-operative monitoring of gastric cancer.

Eligibility Criteria

Inclusion Criteria: 1. Subject age over 18. 2. Subject has stomach discomfort, and seek medical attention at the Gastric Surgery Department of our center. 3. Subject has or will have gastroscopy and/or pathological examination results at this center. 4. Subject must be able to fully understand the informed consent form and be able to personally sign it. Exclusion Criteria: 1. Subject has serious heart, liver, kidney dysfunction, or mental illness. 2. Subject diagnosed previously with any kind of malignant tumor. 3. Subject is known to be infected with HIV or other related diseases (considering interference from the use of immune drugs). 4. Subject is receiving targeted drugs, immunosuppressants, immunomodulators, and biological therapies. 5. Researchers believe that subject is not suitable for enrollment. 6. Subject can not supply sufficient sample to complete this experiment.

Contact & Investigator

Central Contact

Dazhi Xu, MD., PhD,

✉ jiangnan@sz-hoho.com

📞 +86 13862036541

Principal Investigator

Dazhi Xu, MD., PhD,

PRINCIPAL INVESTIGATOR

Fudan University

Frequently Asked Questions

Who can join the NCT07026240 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07026240 currently recruiting?

Yes, NCT07026240 is actively recruiting participants. Contact the research team at jiangnan@sz-hoho.com for enrollment information.

Where is the NCT07026240 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT07026240 clinical trial?

NCT07026240 is sponsored by Suzhou Huhu Health & Technology Inc.. The principal investigator is Dazhi Xu, MD., PhD, at Fudan University. The trial plans to enroll 258 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology